Home » Stocks » VECT

VectivBio Holding AG (VECT)

Stock Price: $16.41 USD -0.01 (-0.06%)
Updated Jun 16, 2021 4:00 PM EDT - Market closed
Market Cap 558.18M
Revenue (ttm) n/a
Net Income (ttm) -59.94M
Shares Out 34.01M
EPS (ttm) -1.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 16
Last Price $16.41
Previous Close $16.42
Change ($) -0.01
Change (%) -0.06%
Day's Open 16.61
Day's Range 16.01 - 16.75
Day's Volume 31,893
52-Week Range 12.62 - 37.70

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Phase 2 trial will evaluate the efficacy of once-weekly apraglutide in increasing intestinal energy absorption in CIC patients with SBS-IF CIC patients represent over half of the total SBS-IF population...

1 day ago - GlobeNewsWire

Christian Meyer, currently Chief Development Officer, to assume the newly created position of Chief Operating Officer Senior leadership appointments strengthen VectivBio as it continues development of a...

3 weeks ago - GlobeNewsWire

BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- In a press release issued under the same headline earlier today by VectivBio Holding AG (Nasdaq: VECT), please note that in the first sentence of t...

2 months ago - GlobeNewsWire

BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development an...

2 months ago - GlobeNewsWire

Biotech stocks are making headlines on Friday as two companies join the public market via initial public offerings (IPOs) today. The post Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM...

Other stocks mentioned: RPHM
2 months ago - InvestorPlace

VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical...

2 months ago - GlobeNewswire

VectivBio Holding, a Swiss Phase 3 biotech developing therapies for rare gastrointestinal disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

2 months ago - NASDAQ

VectivBio Holding AG has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC

About VECT

VectivBio Holding is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. Our goal is to become a leading, patient-centric, fully integrated global rare disease company. Our current product pipeline is focused on rare gastrointestinal, or GI, disorders, and we intend to in-license or acquire additional transformational, differentiated rare disease assets. Our product candidate, apraglutide, i... [Read more...]

Industry
Research and Development in Biotechnology
IPO Date
Apr 9, 2021
Stock Exchange
NASDAQ
Ticker Symbol
VECT
Full Company Profile

Financial Performance

Financial Statements